Steel Partners Holdings has made an unsolicited cash offer of $16.75 per share to acquire InMode Ltd., the Israeli-listed RF microneedling and energy-device manufacturer. The bid directly challenges a competing CEO-led buyout proposal and signals activist pressure on the company's valuation and strategic direction.
Business & M&A
Steel Partners Bids $16.75 Per Share for InMode — Unsolicited Offer Challenges CEO Buyout
Activist investor Steel Partners launches rival cash offer for the RF microneedling and energy-device maker.
Steel Partners' $16.75-per-share bid challenges the CEO-led alternative and signals activist pressure on device-maker valuations.
InMode's core franchises—Morpheus8 (fractional RF microneedling), Lumenis Ultra (diode laser), and Forma (monopolar RF)—command significant installed bases across North American medspas and dermatology practices. The competing bids underscore investor appetite for consolidated device platforms, particularly as practices consolidate and MSOs scale. The outcome will shape access terms, pricing, and service support for practices currently running InMode equipment.
Source: original report ↗
Frequently asked questions
What is Steel Partners' offer price for InMode and how does it compare to the CEO buyout?
Steel Partners bid $16.75 per share in an unsolicited cash offer to acquire InMode. The article does not disclose the CEO-led proposal price, but the competing bids indicate investor disagreement over the company's valuation and strategic direction.
What InMode devices are most used in medspas and how could a buyout affect them?
Morpheus8 (fractional RF microneedling), Lumenis Ultra (diode laser), and Forma (monopolar RF) are InMode's core franchises with significant installed bases across North American medspas and dermatology practices. The acquisition outcome will likely shape access terms, pricing, and service support for practices currently using these devices.
Why is Steel Partners making an unsolicited bid for InMode?
Steel Partners is an activist investor signaling pressure on InMode's valuation and strategic direction. The competing bids reflect broader investor appetite for consolidated device platforms, especially as medical practices and MSOs scale and consolidate.
How could InMode's acquisition affect medspas and dermatology practices?
The acquisition outcome will directly impact device access, pricing, and service support for practices currently running InMode equipment. Consolidation of device platforms under a new owner could reshape terms and availability for medspas relying on Morpheus8, Lumenis Ultra, and Forma devices.
What does an unsolicited bid mean for InMode shareholders and the company's future?
An unsolicited bid means Steel Partners is offering to buy InMode without management approval, creating a competing offer against the CEO-led buyout proposal. This puts pressure on the board to evaluate both offers and determine which best serves shareholder interests.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Seasoned Expat Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.